Literature DB >> 33635442

Consensus guidelines for botulinum toxin therapy: general algorithms and dosing tables for dystonia and spasticity.

Dirk Dressler1, Maria Concetta Altavista2, Eckart Altenmueller3, Roongroj Bhidayasiri4, Saeed Bohlega5, Pedro Chana6, Tae Mo Chung7, Carlo Colosimo8, Klemens Fheodoroff9, Pedro J Garcia-Ruiz10, Beomseok Jeon11, Lingjing Jin12, Petr Kanovsky13, Ivan Milanov14, Federico Micheli15, Olga Orlova16, Sanjay Pandey17, Zvezdan Pirtosek18, Maja Relja19, Raymond Rosales20, José Alberto Sagástegui-Rodríguez21, Gholam Ali Shahidi22, Sofia Timerbaeva23, Xinhua Wan24, Uwe Walter25, Fereshte Adib Saberi26.   

Abstract

Botulinum toxin (BT) therapy is a complex and highly individualised therapy defined by treatment algorithms and injection schemes describing its target muscles and their dosing. Various consensus guidelines have tried to standardise and to improve BT therapy. We wanted to update and improve consensus guidelines by: (1) Acknowledging recent advances of treatment algorithms. (2) Basing dosing tables on statistical analyses of real-life treatment data of 1831 BT injections in 36 different target muscles in 420 dystonia patients and 1593 BT injections in 31 different target muscles in 240 spasticity patients. (3) Providing more detailed dosing data including typical doses, dose variabilities, and dosing limits. (4) Including total doses and target muscle selections for typical clinical entities thus adapting dosing to different aetiologies and pathophysiologies. (5) In addition, providing a brief and concise review of the clinical entity treated together with general principles of its BT therapy. For this, we collaborated with IAB-Interdisciplinary Working Group for Movement Disorders which invited an international panel of experts for the support.

Entities:  

Keywords:  Botulinum toxin; Consensus guidelines; Dose limits; Dose variability; Dosing tables; Dystonia; Spasticity; Target muscles; Therapy; Total dose; Treatment algorithms; Typical dose

Year:  2021        PMID: 33635442      PMCID: PMC7969540          DOI: 10.1007/s00702-021-02312-4

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  17 in total

1.  Measuring the potency labelling of onabotulinumtoxinA (Botox(®)) and incobotulinumtoxinA (Xeomin (®)) in an LD50 assay.

Authors:  Dirk Dressler; Gerd Mander; Klaus Fink
Journal:  J Neural Transm (Vienna)       Date:  2011-10-05       Impact factor: 3.575

2.  Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology.

Authors:  David M Simpson; Mark Hallett; Eric J Ashman; Cynthia L Comella; Mark W Green; Gary S Gronseth; Melissa J Armstrong; David Gloss; Sonja Potrebic; Joseph Jankovic; Barbara P Karp; Markus Naumann; Yuen T So; Stuart A Yablon
Journal:  Neurology       Date:  2016-04-18       Impact factor: 9.910

Review 3.  Injection techniques for botulinum toxin using electromyography and electrical stimulation.

Authors:  C F O'Brien
Journal:  Muscle Nerve Suppl       Date:  1997

4.  Comparing incobotulinumtoxinA (Xeomin®) and onabotulinumtoxinA (Botox®): identical potency labelling in the hemidiaphragm assay.

Authors:  Dirk Dressler; Lizhen Pan; Hans Bigalke
Journal:  J Neural Transm (Vienna)       Date:  2018-06-26       Impact factor: 3.575

5.  EFNS guidelines on diagnosis and treatment of primary dystonias.

Authors:  A Albanese; F Asmus; K P Bhatia; A E Elia; B Elibol; G Filippini; T Gasser; J K Krauss; N Nardocci; A Newton; J Valls-Solé
Journal:  Eur J Neurol       Date:  2011-01       Impact factor: 6.089

6.  Safety of botulinum toxin short interval therapy using incobotulinumtoxin A.

Authors:  Dirk Dressler; Fereshte Adib Saberi
Journal:  J Neural Transm (Vienna)       Date:  2016-10-17       Impact factor: 3.575

7.  Treatment with botulinum toxin in a patient with myasthenia gravis and cervical dystonia.

Authors:  A Fasano; A R Bentivoglio; T Ialongo; F Soleti; A Evoli
Journal:  Neurology       Date:  2005-06-28       Impact factor: 9.910

Review 8.  Dosing, administration, and a treatment algorithm for use of botulinum toxin A for adult-onset spasticity. Spasticity Study Group.

Authors:  M F Brin
Journal:  Muscle Nerve Suppl       Date:  1997

9.  Safety aspects of incobotulinumtoxinA high-dose therapy.

Authors:  Dirk Dressler; Fereshte Adib Saberi; Katja Kollewe; Christoph Schrader
Journal:  J Neural Transm (Vienna)       Date:  2014-07-17       Impact factor: 3.575

10.  Botulinum toxin therapy of cervical dystonia: duration of therapeutic effects.

Authors:  Dirk Dressler; Pawel Tacik; Fereshte Adib Saberi
Journal:  J Neural Transm (Vienna)       Date:  2014-07-23       Impact factor: 3.575

View more
  10 in total

1.  Untwisting dystonia: stepping-up genetics, shifting pathophysiology, and strategizing care.

Authors:  Raymond L Rosales; Ana Westenberger
Journal:  J Neural Transm (Vienna)       Date:  2021-04-30       Impact factor: 3.575

2.  OnabotulinumtoxinA Dosing, Disease Severity, and Treatment Benefit in Patients With Cervical Dystonia: A Cohort Analysis From CD PROBE.

Authors:  Pinky Agarwal; Richard Barbano; Henry Moore; Marc Schwartz; Aleksej Zuzek; Marjan Sadeghi; Atul Patel
Journal:  Front Neurol       Date:  2022-06-30       Impact factor: 4.086

3.  COVID-19-related delays of botulinum toxin injections have a negative impact on the quality of life of patients with dystonia and spasticity: a single-center ambulatory care study.

Authors:  Yvonne Teuschl; Christian Bancher; Michael Brainin; Alexandra Dachenhausen; Karl Matz; Michaela M Pinter
Journal:  J Neural Transm (Vienna)       Date:  2021-10-23       Impact factor: 3.575

4.  Comparative Effectiveness of Botulinum Toxin Injections and Extracorporeal Shockwave Therapy for Post-Stroke Spasticity: A Systematic Review and Network Meta-Analysis.

Authors:  Po-Cheng Hsu; Ke-Vin Chang; Yi-Hsiang Chiu; Wei-Ting Wu; Levent Özçakar
Journal:  EClinicalMedicine       Date:  2021-12-04

Review 5.  Botulinum Toxin Therapy for Oromandibular Dystonia and Other Movement Disorders in the Stomatognathic System.

Authors:  Kazuya Yoshida
Journal:  Toxins (Basel)       Date:  2022-04-14       Impact factor: 5.075

Review 6.  Botulinum toxin therapy: past, present and future developments.

Authors:  Dirk Dressler; Eric A Johnson
Journal:  J Neural Transm (Vienna)       Date:  2022-04-09       Impact factor: 3.850

Review 7.  Patient selection and injection techniques for botulinum neurotoxin in oromandibular dystonia.

Authors:  Roongroj Bhidayasiri; Suppata Maytharakcheep; Daniel D Truong
Journal:  Clin Park Relat Disord       Date:  2022-08-05

8.  Retroform Cervical Dystonia: Target Muscle Selection and Efficacy of Botulinum Toxin Injection.

Authors:  Yaowen Hu; Lizhen Pan; Junhui Su; Shuzhen Chen; Xiaolong Zhang; Yougui Pan; Lingjing Jin; Fei Teng
Journal:  Front Neurol       Date:  2022-07-26       Impact factor: 4.086

9.  Nonlinear Changes in Botulinum Toxin Treatment of Task-Specific Dystonia during Long-Term Treatment.

Authors:  André Lee; Jabreel Al-Sarea; Eckart Altenmüller
Journal:  Toxins (Basel)       Date:  2021-05-22       Impact factor: 4.546

Review 10.  Botulinum toxin therapy of dystonia.

Authors:  Dirk Dressler; Fereshte Adib Saberi; Raymond L Rosales
Journal:  J Neural Transm (Vienna)       Date:  2020-10-30       Impact factor: 3.575

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.